Oligometastatic Prostate Carcinoma — Trials

Oligometastatic Prostate Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

11 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 9
Recruiting: 2
Ph III recruiting: 0
Growth YoY: —
Industry share: 11%
Top sponsor: Mayo Clinic
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06229366	[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer(ACCEL)	active not recruiting	Phase 1	142	Eli Lilly and CompanyINDUSTRY	1	Dec 22, 2025	clinicaltrials

Data updated 22 days agoSource updated Dec 22, 2025source: clinicaltrials